LPAR5 and neoplasm: Third, LPAR5 as a new immunotherapy target still lacks direct evidence, and it will be necessary to verify whether LPAR5 can inhibit tumor growth or benefit the prognosis of patients through clinical trials of relevant targeted therapies.